Vaughn Byron Philip, Moss Alan Colm
Byron Philip Vaughn, Alan Colm Moss, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Boston, MA 02115, United States.
World J Gastroenterol. 2014 Feb 7;20(5):1147-54. doi: 10.3748/wjg.v20.i5.1147.
Endoscopic and clinical recurrence of Crohn's disease (CD) is a common occurrence after surgical resection. Smokers, those with perforating disease, and those with myenteric plexitis are all at higher risk of recurrence. A number of medical therapies have been shown to reduce this risk in clinical trials. Metronidazole, thiopurines and anti-tumour necrosis factors (TNFs) are all effective in reducing the risk of endoscopic or clinical recurrence of CD. Since these are preventative agents, the benefits of prophylaxis need to be weighed-against the risk of adverse events from, and costs of, therapy. Patients who are high risk for post-operative recurrence should be considered for early medical prophylaxis with an anti-TNF. Patients who have few to no risk factors are likely best served by a three-month course of antibiotics followed by tailored therapy based on endoscopy at one year. Clinical recurrence rates are variable, and methods to stratify patients into high and low risk populations combined with prophylaxis tailored to endoscopic recurrence would be an effective strategy in treating these patients.
克罗恩病(CD)内镜及临床复发在手术切除后很常见。吸烟者、患有穿孔性疾病者以及患有肌间神经丛炎者复发风险更高。多项药物治疗在临床试验中已显示可降低这种风险。甲硝唑、硫唑嘌呤和抗肿瘤坏死因子(TNF)在降低CD内镜或临床复发风险方面均有效。由于这些是预防药物,预防的益处需要与治疗的不良事件风险及费用相权衡。术后复发高危患者应考虑早期使用抗TNF进行药物预防。几乎没有或没有风险因素的患者可能最好先接受为期三个月的抗生素治疗,然后根据一年后的内镜检查结果进行个体化治疗。临床复发率各不相同,将患者分层为高风险和低风险人群并结合针对内镜复发的预防措施的方法将是治疗这些患者的有效策略。